CareDx Reports Strong Q1, Raises Guidance, Acquires Naveris for up to $260M, and Authorizes $100M Buyback
CDNA sits 88% above its 52-week low of $10.96.
Summary
CareDx reported robust Q1 earnings with raised guidance, announced a strategic acquisition of Naveris for up to $260 million, and authorized a new $100 million share repurchase program.
Key Events · M&A and Partnerships · CDNA
-
Strategic Acquisition of Naveris, Inc.
CareDx entered into a definitive agreement to acquire Naveris, Inc. for an upfront cash consideration of $160 million, with up to an additional $100 million contingent on revenue-based milestones. This acquisition expands CareDx's precision medicine testing services into the specialty oncology market.
-
Strong Q1 2026 Financial Results
The company reported first-quarter 2026 revenue of $118 million, a 39% increase year-over-year, driven by strong performance in testing services and patient and digital solutions. GAAP net income was $3 million, compared to a $10 million loss in Q1 2025, and Adjusted EBITDA reached $19 million.
-
Raised Full-Year 2026 Guidance
CareDx raised its full-year 2026 revenue guidance to a range of $447 million to $465 million (from $420 million-$444 million) and its Adjusted EBITDA guidance to $43 million to $57 million, reflecting confidence in continued growth and profitability.
-
New $100 Million Share Repurchase Program
The Board of Directors authorized a new common stock repurchase program of up to $100 million, effective for up to 24 months from April 30, 2026. This program is separate from a prior $50 million authorization.
Analysis · CDNA · Industrial Applications And Services
CareDx, Inc. has filed an 8-K detailing several significant market-moving events. The company announced a definitive agreement to acquire Naveris, Inc., a leader in viral-mediated cancer MRD surveillance testing, for an upfront cash consideration of $160 million and up to an additional $100 million contingent on revenue milestones. This strategic acquisition expands CareDx's precision medicine testing services into specialty oncology, a new high-growth market. Concurrently, CareDx reported strong first-quarter 2026 financial results, with revenue increasing 39% year-over-year to $118 million and Adjusted EBITDA reaching $19 million, a substantial improvement from the prior year. Reflecting this performance, the company raised its full-year 2026 revenue guidance to $447 million-$465 million and Adjusted EBITDA guidance to $43 million-$57 million. Additionally, the Board of Directors authorized a new common stock repurchase program of up to $100 million over 24 months, signaling confidence in future performance and a commitment to shareholder returns. These combined announcements indicate a strong financial position, strategic expansion, and proactive capital management.
At the time of this filing, CDNA was trading at $20.58 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $10.96 to $23.24. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.